Advances in drug delivery to atherosclerosis: Investigating the efficiency of different nanomaterials employed for different type of drugs

Tsao, 2022, Heart disease and stroke statistics—2022 update: a report from the American heart association, Circulation, 145, e153, 10.1161/CIR.0000000000001052 2021, World Health Statistics 2021: A Visual Summary Libby, 2019, Atherosclerosis. Nature Reviews Disease Primers., 5, 56, 10.1038/s41572-019-0106-z Ndrepepa, 2017, Atherosclerosis & ischaemic heart disease: here to stay or gone tomorrow, Indian J. Med. Res., 146, 293 Seidman, 2014, Pathophysiology of atherosclerosis, 221 Ta, 2018, Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis, Nanoscale, 10, 15103, 10.1039/C8NR05095C Liu, 2019, Investigating the use of layered double hydroxide nanoparticles as carriers of metal oxides for theranostics of ROS-related diseases, ACS Appl. Nano Mater., 2, 5930, 10.1021/acsabm.9b00852 Wu, 2021, Chitosan nanococktails containing both ceria and superparamagnetic iron oxide nanoparticles for reactive oxygen species-related theranostics, ACS Appl. Nano Mater., 4, 3604, 10.1021/acsanm.1c00141 Wu, 2021, Engineering chitosan nano-cocktail containing iron oxide and ceria: a two-in-one approach for treatment of inflammatory diseases and tracking of material delivery, Mater. Sci. Eng. C, 131, 10.1016/j.msec.2021.112477 Akther, 2022, Atherothrombosis‐on‐Chip: a site‐specific microfluidic model for thrombus formation and drug discovery, ADvanced Biology, 6 Vazquez-Prada, 2023, A spiky silver-iron oxide nanoparticle for highly efficient targeted photothermal therapy and multimodal imaging of thrombosis, Small, 19 Wentzel, 2012, Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular remodelling: current understanding and remaining questions, Cardiovasc. Res., 96, 234, 10.1093/cvr/cvs217 Warboys, 2011, The role of blood flow in determining the sites of atherosclerotic plaques, F1000 Med Rep, 3, 5, 10.3410/M3-5 Zhang, 2019, Treatment of atherosclerotic plaque: perspectives on theranostics, J. Pharm. Pharmacol., 71, 1029, 10.1111/jphp.13092 Saini, 2005, Pharmacological basis of different targets for the treatment of atherosclerosis, J. Cell Mol. Med., 9, 818, 10.1111/j.1582-4934.2005.tb00382.x Saçlı, 2018 Zisko, 2017, Personal activity intelligence (PAI), sedentary behavior and cardiovascular risk factor clustering - the HUNT study, Prog. Cardiovasc. Dis., 60, 89, 10.1016/j.pcad.2017.02.007 Ibanez, 2009, Diagnosis of atherosclerosis by imaging, Am. J. Med., 122, S15, 10.1016/j.amjmed.2008.10.014 Ridker, 2017, Antiinflammatory therapy with Canakinumab for atherosclerotic disease, N. Engl. J. Med., 377, 1119, 10.1056/NEJMoa1707914 Ridker, 2018, Low-dose methotrexate for the prevention of atherosclerotic events, N. Engl. J. Med., 380, 752, 10.1056/NEJMoa1809798 Nidorf, 2013, Low-dose colchicine for secondary prevention of cardiovascular disease, J. Am. Coll. Cardiol., 61, 404, 10.1016/j.jacc.2012.10.027 Tardif, 2019, Efficacy and safety of low-dose colchicine after myocardial infarction, N. Engl. J. Med., 381, 2497, 10.1056/NEJMoa1912388 Tong, 2020, Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial, Circulation, 142, 1890, 10.1161/CIRCULATIONAHA.120.050771 Ma, 2020, Anti-inflammatory therapy for coronary atherosclerotic heart disease: unanswered questions behind existing successes, Frontiers in Cardiovascular Medicine, 7 Ward, 2019, Statin toxicity: mechanistic insights and clinical implications, Circ. Res., 124, 328, 10.1161/CIRCRESAHA.118.312782 Ingram, 2005, Peripheral intravenous therapy: key risks and implications for practice, Nurs. Stand., 19, 55+ Sahoo, 2021, Chapter 9 - oral drug delivery of nanomedicine, 181 Montrief, 2018, Coronary artery bypass graft surgery complications: a review for emergency clinicians, Am. J. Emerg. Med., 36, 2289, 10.1016/j.ajem.2018.09.014 Saha, 2015, Carotid endarterectomy: current concepts and practice patterns, Int. J. Angiol., 24, 223, 10.1055/s-0035-1558645 Giannini, 2018, A practical approach to the management of complications during percutaneous coronary intervention, JACC Cardiovasc. Interv., 11, 1797, 10.1016/j.jcin.2018.05.052 Perera, 2022, Percutaneous revascularization for ischemic left ventricular dysfunction, N. Engl. J. Med., 382, 1351, 10.1056/NEJMoa2206606 Hu, 2022, Nanotechnology for cardiovascular diseases, Innovation, 3 Pala, 2020, Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases, Int. J. Nanomed., 15, 3741, 10.2147/IJN.S250872 Chopra, 2022, Nanomaterials: a promising therapeutic approach for cardiovascular diseases, J. Nanomater., 2022, 10.1155/2022/4155729 Ta, 2017, Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast, Biomaterials, 134, 31, 10.1016/j.biomaterials.2017.04.037 Ta, 2018, The effects of particle size, shape, density and flow characteristics on particle margination to vascular walls in cardiovascular diseases, Expet Opin. Drug Deliv., 15, 33, 10.1080/17425247.2017.1316262 Zhang, 2019, Treatment of atherosclerotic plaque: perspectives on theranostics, J. Pharm. Pharmacol., 71, 1029, 10.1111/jphp.13092 Vazquez-Prada, 2021, Targeted molecular imaging of cardiovascular diseases by iron oxide nanoparticles, Arterioscler. Thromb. Vasc. Biol., 41, 601, 10.1161/ATVBAHA.120.315404 Yusof, 2019, Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis, Thromb. Res., 177, 161, 10.1016/j.thromres.2019.03.009 Ta, 2012, Enzymatic antibody tagging: toward a universal biocompatible targeting tool, Trends Cardiovasc. Med., 22, 105, 10.1016/j.tcm.2012.07.004 Arndt, 2020, Different approaches to develop nanosensors for diagnosis of diseases, Adv. Sci., 7, 10.1002/advs.202001476 Wu, 2021, Recent advances in the development of theranostic nanoparticles for cardiovascular diseases, Nanotheranostics, 5, 499, 10.7150/ntno.62730 Wu, 2021, Different approaches to synthesising cerium oxide nanoparticles and their corresponding physical characteristics, and ROS scavenging and anti-inflammatory capabilities, J. Mater. Chem. B, 9, 7291, 10.1039/D1TB01091C Prilepskii, 2020, Nanoparticle-based approaches towards the treatment of atherosclerosis, Pharmaceutics, 12, 1056, 10.3390/pharmaceutics12111056 Peters, 2020, Nanomaterials to resolve atherosclerosis, ACS Biomater. Sci. Eng., 6, 3693, 10.1021/acsbiomaterials.0c00281 Flores, 2019, Nanoparticle therapy for vascular diseases, Arterioscler. Thromb. Vasc. Biol., 39, 635, 10.1161/ATVBAHA.118.311569 Hossaini Nasr, 2021, Nanotechnology for targeted therapy of atherosclerosis, Front. Pharmacol., 12, 10.3389/fphar.2021.755569 Bejarano, 2018, Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches, Theranostics, 8, 4710, 10.7150/thno.26284 Liu, 2022, Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis, J. Nanobiotechnol., 20, 75, 10.1186/s12951-022-01279-y Chen, 2020, Recent progress in the detection and treatment of atherosclerosis by nanoparticles, Mater. Today Chem., 17 Dai, 2020, Applications of inorganic nanoparticles in the diagnosis and therapy of atherosclerosis, Biomater. Sci., 8, 3784, 10.1039/D0BM00196A Sayers, 2022, Database resources of the national center for biotechnology information, Nucleic Acids Res., 50, 10.1093/nar/gkab1112 Patra, 2018, Nano based drug delivery systems: recent developments and future prospects, J. Nanobiotechnol., 16, 1, 10.1186/s12951-018-0392-8 Pelaz, 2017, Diverse applications of nanomedicine, ACS Nano, 11, 2313, 10.1021/acsnano.6b06040 Nakhlband, 2018, Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective, Bioimpacts, 8, 59, 10.15171/bi.2018.08 Sanità, 2020, Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization, Front. Mol. Biosci., 7, 381, 10.3389/fmolb.2020.587012 Zia, 2020, The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis, Cardiovasc. Res., 116, 2055, 10.1093/cvr/cvaa047 Huang, 2021, Nanotechnology for targeted therapy of atherosclerosis, Front. Pharmacol., 12 Mirchandani, 2021, Solid lipid nanoparticles for hydrophilic drugs, J. Contr. Release, 335, 457, 10.1016/j.jconrel.2021.05.032 Arpicco, 2016, Recent studies on the delivery of hydrophilic drugs in nanoparticulate systems, J. Drug Deliv. Sci. Technol., 32, 298, 10.1016/j.jddst.2015.09.004 Kalepu, 2015, Insoluble drug delivery strategies: review of recent advances and business prospects, Acta Pharm. Sin. B, 5, 442, 10.1016/j.apsb.2015.07.003 Fumoto, 2020, Co-Delivery systems of multiple drugs using nanotechnology for future cancer therapy, Chem. Pharm. Bull. (Tokyo), 68, 603, 10.1248/cpb.c20-00008 Al Bostami, 2022, Recent advances in nanoparticle-based Co-delivery systems for cancer therapy, Nanomaterials, 12, 10.3390/nano12152672 Meng, 2020, Rational design and latest advances of codelivery systems for cancer therapy, Mater Today Bio, 7 Carvalho, 2021, Recent advances in co-delivery nanosystems for synergistic action in cancer treatment, J. Mater. Chem. B, 9, 1208, 10.1039/D0TB02168G Zhao, 2022, A ROS-responsive simvastatin nano-prodrug and its fibronectin-targeted Co-delivery system for atherosclerosis treatment, ACS Appl. Mater. Interfaces, 14, 25080, 10.1021/acsami.2c02354 Wu, 2021, Degradable co-delivery nanoplatforms for inflammation-targeted therapy against atherosclerosis, Appl. Mater. Today, 25 Zhao, 2018, Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: a dual cell therapy to regress plaques, J. Contr. Release, 283, 241, 10.1016/j.jconrel.2018.05.041 Xu, 2023, A metal-organic framework-based immunomodulatory nanoplatform for anti-atherosclerosis treatment, J. Contr. Release, 354, 615, 10.1016/j.jconrel.2023.01.024 Li, 2019, Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis, Int. J. Nanomed., 14, 649, 10.2147/IJN.S189819 Huang, 2023, Co-delivery of therapeutics and bioactive gas using a novel liposomal platform for enhanced treatment of acute arterial injury, Biomolecules, 13, 861, 10.3390/biom13050861 Li, 2023, Liposomal codelivery of inflammation inhibitor and collagen protector to the plaque for effective anti-atherosclerosis, Chin. Chem. Lett., 34, 10.1016/j.cclet.2022.04.081 Pillai, 2021, Co-delivery of curcumin and bioperine via PLGA nanoparticles to prevent atherosclerotic foam cell formation, Pharmaceutics, 13, 1420, 10.3390/pharmaceutics13091420 Wu, 2018, Co-Delivery of andrographolide and notch1-targeted siRNA to macrophages with polymer-based nanocarrier for enhanced anti-inflammation, Chin. J. Polym. Sci., 36, 1312, 10.1007/s10118-018-2158-z Liu, 2022, Tanshinone IIA-loaded micelles functionalized with rosmarinic acid: a novel synergistic anti-inflammatory strategy for treatment of atherosclerosis, J. Pharmaceut. Sci., 111, 2827, 10.1016/j.xphs.2022.05.007 Almeida, 2019, Effect of statins on atherosclerotic plaque, Trends Cardiovasc. Med., 29, 451, 10.1016/j.tcm.2019.01.001 Pinal-Fernandez, 2018, Statins: pros and cons, Med. Clin., 150, 398, 10.1016/j.medcli.2017.11.030 Beltowski, 2009, Adverse effects of statins - mechanisms and consequences, Curr. Drug Saf., 4, 209, 10.2174/157488609789006949 Mason, 2003, Statins and their role in vascular protection, Clin. Sci., 105, 251, 10.1042/CS20030148 Dallner, 1982, Synthesis of membrane glycoproteins, Tokai J. Exp. Clin. Med., 7, 73 Marcoff, 2007, The role of coenzyme Q10 in statin-associated myopathy, J. Am. Coll. Cardiol., 49, 2231, 10.1016/j.jacc.2007.02.049 Greenwood, 2006, Statin therapy and autoimmune disease: from protein prenylation to immunomodulation, Nat. Rev. Immunol., 6, 358, 10.1038/nri1839 Bittencourt, 2015, Statin effects on atherosclerotic plaques: regression or healing?, BMC Med., 13, 1, 10.1186/s12916-015-0499-9 Katsuki, 2014, Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes, Circulation, 129, 896, 10.1161/CIRCULATIONAHA.113.002870 Gao, 2020, Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines, Nat. Commun., 11, 1, 10.1038/s41467-020-16439-7 Hossaini Nasr, 2020, Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles, Nanoscale, 12, 9541, 10.1039/D0NR00308E Wan, 2023, Anti-oxidative, anti-apoptotic, and M2 polarized DSPC liposome nanoparticles for selective treatment of atherosclerosis, Int. J. Nanomed., 18, 579, 10.2147/IJN.S384675 Duivenvoorden, 2014, A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation, Nat. Commun., 5, 1 Zhang, 2017, Plaque-hyaluronidase-responsive high-density-lipoprotein-mimetic nanoparticles for multistage intimal-macrophage-targeted drug delivery and enhanced anti-atherosclerotic therapy, Int. J. Nanomed., 12, 533, 10.2147/IJN.S124252 Kim, 2020, Affinity-driven design of cargo-switching nanoparticles to leverage a cholesterol-rich microenvironment for atherosclerosis therapy, ACS Nano, 14, 6519, 10.1021/acsnano.9b08216 Mu, 2020, Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis, J. Nanobiotechnol., 18, 179, 10.1186/s12951-020-00744-w Liu, 2014, Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions, Biomaterials, 35, 8002, 10.1016/j.biomaterials.2014.05.081 Kim, 2021, Targeting and clearance of senescent foamy macrophages and senescent endothelial cells by antibody-functionalized mesoporous silica nanoparticles for alleviating aorta atherosclerosis, Biomaterials, 269 Simonsen, 2016, Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform–a detailed survey of rHDL particles ranging from biophysical properties to clinical implications, Nanomed. Nanotechnol. Biol. Med., 12, 2161, 10.1016/j.nano.2016.05.009 Boccardi, 2014, The association between statins and telomere shortening, Clin. Lipidol., 9, 311, 10.2217/clp.14.21 Krolikoski, 2019, The CD44-HA axis and inflammation in atherosclerosis: a temporal perspective, Matrix Biol., 78–79, 201, 10.1016/j.matbio.2018.05.007 Mäkinen, 2020, Nucleic acid–based therapies for atherosclerosis, Curr. Atherosclerosis Rep., 22, 1, 10.1007/s11883-020-0826-2 Sager, 2016, RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction, Sci. Transl. Med., 8, 10.1126/scitranslmed.aaf1435 Majmudar, 2013, Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques, Circ. Res., 112, 755, 10.1161/CIRCRESAHA.111.300576 Kowalski, 2013, Anti-VCAM-1 and anti-E-selectin SAINT-O-Somes for selective delivery of siRNA into inflammation-activated primary endothelial cells, Mol. Pharm., 10, 3033, 10.1021/mp4001124 Ma, 2016, E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis, Sci. Rep., 6, 1 Leuschner, 2011, Therapeutic siRNA silencing in inflammatory monocytes in mice, Nat. Biotechnol., 29, 1005, 10.1038/nbt.1989 Kheirolomoom, 2015, Multifunctional nanoparticles facilitate molecular targeting and miRNA delivery to inhibit atherosclerosis in ApoE–/–mice, ACS Nano, 9, 8885, 10.1021/acsnano.5b02611 Sun, 2016, Targeted delivery of anti‐miR‐712 by VCAM1‐binding Au nanospheres for atherosclerosis therapy, Chemnanomat, 2, 400, 10.1002/cnma.201600043 Li, 2020, Site-specific MicroRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity, Adv. Funct. Mater., 30, 10.1002/adfm.202002131 Gao, 2018, H2O2-responsive and plaque-penetrating nanoplatform for mTOR gene silencing with robust anti-atherosclerosis efficacy, Chem. Sci., 9, 439, 10.1039/C7SC03582A Bai, 2022, Scavenger receptor-targeted plaque delivery of microRNA-coated nanoparticles for alleviating atherosclerosis, Proc. Natl. Acad. Sci. USA, 119, 10.1073/pnas.2201443119 Ono, 2016, Functions of microRNA-33a/b and microRNA therapeutics, J. Cardiol., 67, 28, 10.1016/j.jjcc.2015.10.017 Zhang, 2019, Promoting the delivery of nanoparticles to atherosclerotic plaques by DNA coating, ACS Appl. Mater. Interfaces, 11, 13888, 10.1021/acsami.8b17928 Stigliano, 2017, Methotraxate-loaded hybrid nanoconstructs target vascular lesions and inhibit atherosclerosis progression in ApoE−/− mice, Adv. Healthcare Mater., 6, 10.1002/adhm.201601286 Bartneck, 2014, Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages, Nanomed. Nanotechnol. Biol. Med., 10, 1209, 10.1016/j.nano.2014.02.011 Bulgarelli, 2013, Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits, Cardiovasc. Drugs Ther., 27, 531, 10.1007/s10557-013-6488-3 A, 2017, Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study, J Biomed Res, 31, 116, 10.7555/JBR.31.20160123 Freitas, 2018, Lipid core nanoparticles resembling low-density lipoprotein and regression of atherosclerotic lesions: effects of particle size, Braz. J. Med. Biol. Res., 51, 1, 10.1590/1414-431x20177090 Gomes, 2018, Regression of atherosclerotic plaques of cholesterol-fed rabbits by combined chemotherapy with paclitaxel and methotrexate carried in lipid core nanoparticles, J. Cardiovasc. Pharmacol. Therapeut., 23, 561, 10.1177/1074248418778836 Meneghini, 2019, Lipid core nanoparticles as vehicle for docetaxel reduces atherosclerotic lesion, inflammation, cell death and proliferation in an atherosclerosis rabbit model, Vasc. Pharmacol., 115, 46, 10.1016/j.vph.2019.02.003 Bagalkot, 2015, Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals, J. Contr. Release, 217, 243, 10.1016/j.jconrel.2015.09.027 Huang, 2020, Platelet-derived nanomotor coated balloon for atherosclerosis combination therapy, J. Mater. Chem. B, 8, 5765, 10.1039/D0TB00789G Ji, 2021, Antibody-based therapeutics for atherosclerosis and cardiovascular diseases, Int. J. Mol. Sci., 22, 10.3390/ijms22115770 Kim, 2018, Recent development of inorganic nanoparticles for biomedical imaging, ACS Cent. Sci., 4, 324, 10.1021/acscentsci.7b00574 Calin, 2015, VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes, Eur. J. Pharm. Biopharm., 89, 18, 10.1016/j.ejpb.2014.11.016 Yu, 2017, Targeted nanotherapeutics encapsulating liver x receptor agonist gw3965 enhance antiatherogenic effects without adverse effects on hepatic Lipid metabolism in Ldlr−/− mice, Adv. Healthcare Mater., 6, 10.1002/adhm.201700313 Zhang, 2015, Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis, Adv. Healthcare Mater., 4, 228, 10.1002/adhm.201400337 Wang, 2021, Theranostic nanoplatform to target macrophages enables the inhibition of atherosclerosis progression and fluorescence imaging of plaque, J. Nanobiotechnol., 19, 222, 10.1186/s12951-021-00962-w Dou, 2017, Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis, Biomaterials, 143, 93, 10.1016/j.biomaterials.2017.07.035 Nakashiro, 2016, Pioglitazone-incorporated nanoparticles prevent plaque destabilization and rupture by regulating monocyte/macrophage differentiation in ApoE-/- mice, Arterioscler. Thromb. Vasc. Biol., 36, 491, 10.1161/ATVBAHA.115.307057 Yi, 2019, Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy, Adv. Funct. Mater., 29, 10.1002/adfm.201904399 Flores, 2020, Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis, Nat. Nanotechnol., 15, 154, 10.1038/s41565-019-0619-3 Wang, 2018, Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity, ACS Nano, 12, 8943, 10.1021/acsnano.8b02037 Shi, 2021, Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery, Nanoscale, 13, 10748, 10.1039/D1NR02065J Borgstahl, 2018, 156 Kamaly, 2016, Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis, ACS Nano, 10, 5280, 10.1021/acsnano.6b01114 Fredman, 2015, Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice, Sci. Transl. Med., 7, 10.1126/scitranslmed.aaa1065 Lu, 2021, A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems, Front. Nutr., 8, 10.3389/fnut.2021.783831 Hu, 2019, DNA nanotechnology-enabled drug delivery systems, Chem. Rev., 119, 6459, 10.1021/acs.chemrev.7b00663 Lacroix, 2021, DNA nanostructures: current challenges and opportunities for cellular delivery, ACS Nano, 15, 3631, 10.1021/acsnano.0c06136 Hua, 2018, Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization, Front. Pharmacol., 9, 10.3389/fphar.2018.00790 Cicha, 2018, From design to the clinic: practical guidelines for translating cardiovascular nanomedicine, Cardiovasc. Res., 114, 1714, 10.1093/cvr/cvy219